A Phase 3 interventional study of Evolocumab and Atorvastatin in Primary Hyperlipidemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 2 sites in Australia. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-03.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 27th largest by enrollment, is one of 3 that started in 2014, is one of 22 in phase 3, and was the 20th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 27th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2014, is one of 22 in phase 3, and was the 20th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
Drug: Placebo to Evolocumab · Drug: Placebo to Atorvastatin
Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
Drug: Atorvastatin · Drug: Placebo to Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
Biological: Evolocumab · Drug: Placebo to Atorvastatin
Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
Biological: Evolocumab · Drug: Atorvastatin
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by mouth
Also known as: LIPITOR®
Administered by subcutaneous injection
Administered by mouth
Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)
The fractional catabolic rate (the percentage of apolipoprotein B-100 in LDL which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation, and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.
Time frame: Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.
Percent Change From Baseline in LDL-C at Day 50
LDL-C was measured using ultrcentrifugation.
Time frame: Baseline and Day 50
Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)
The production rate of apolipoprotein B-100 in LDL was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate the production rate.
Time frame: Baseline and Day 50
Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)
The fractional catabolic rate (the percentage of lipoprotein(a) (Lp\[a\]) which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.
Time frame: Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.
Percent Change From Baseline in Lipoprotein(a) Production Rate (PR)
The production rate of lipoprotein(a) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.
Time frame: Baseline and Day 50
This study was conducted at 2 centers in Australia. The first participant was enrolled on 08 July 2014, and the last participant enrolled on 15 December 2014.
| Milestone | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Started | 22 | 23 | 23 | 21 |
| Received treatment | 21 | 22 | 22 | 20 |
| Completed | 20 | 22 | 20 | 19 |
| Not completed | 2 | 1 | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 |
The fractional catabolic rate (the percentage of apolipoprotein B-100 in LDL which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation, and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.
| percent change | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) | -5.07 ± 26.06 | 74.13 ± 24.84 | 83.70 ± 26.06 | 310.48 ± 26.68 |
LDL-C was measured using ultrcentrifugation.
| percent change | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at Day 50 | -0.65 ± 3.09 | -45.25 ± 2.86 | -57.79 ± 3.15 | -83.19 ± 3.24 |
The production rate of apolipoprotein B-100 in LDL was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate the production rate.
| percent change | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR) | -3.80 ± 7.40 | -3.27 ± 7.05 | -20.45 ± 7.40 | -35.93 ± 7.57 |
The fractional catabolic rate (the percentage of lipoprotein(a) (Lp\[a\]) which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.
| percent change | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR) | 7.49 ± 9.17 | 25.52 ± 8.92 | 5.37 ± 9.81 | 64.57 ± 9.23 |
The production rate of lipoprotein(a) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.
| percent change | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) Production Rate (PR) | 3.52 ± 7.94 | -6.88 ± 7.72 | -35.91 ± 8.49 | 16.40 ± 7.99 |
Collected over From first dose of study drug until day 73. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/21 (0%) | 5/21 (23.8%) |
| Atorvastatin | — | 0/22 (0%) | 12/22 (54.5%) |
| Evolocumab | — | 0/22 (0%) | 14/22 (63.6%) |
| Evolocumab and Atorvastatin | — | 1/20 (5%) | 10/20 (50%) |
| Event | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| Liver injuryHepatobiliary disorders | 0/21 | 0/22 | 0/22 | 1/20 |
| Event | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/21 | 5/22 | 8/22 | 7/20 |
| NauseaGastrointestinal disorders | 1/21 | 3/22 | 2/22 | 2/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/21 | 1/22 | 0/22 | 2/20 |
| Abdominal painGastrointestinal disorders | 0/21 | 2/22 | 0/22 | 1/20 |
| Influenza like illnessGeneral disorders | 0/21 | 0/22 | 2/22 | 0/20 |
| NasopharyngitisInfections and infestations | 1/21 | 1/22 | 2/22 | 0/20 |
| PharyngitisInfections and infestations | 0/21 | 2/22 | 1/22 | 0/20 |
| Upper respiratory tract infectionInfections and infestations | 0/21 | 2/22 | 0/22 | 1/20 |
| Blood creatine phosphokinase increasedInvestigations | 0/21 | 2/22 | 0/22 | 1/20 |
| Neck painMusculoskeletal and connective tissue disorders | 0/21 | 2/22 | 1/22 | 0/20 |
The full analysis set includes all randomized participants who received any study drug.
| Age, Continuous(years) | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin | Total |
|---|---|---|---|---|---|
| Mean | 33.9 ± 12.7 | 30.4 ± 7.4 | 33.5 ± 11.6 | 31.0 ± 9.8 | 32.2 ± 10.5 |
| Sex: Female, Male(Participants) | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 21 | 22 | 22 | 20 | 85 |
| Race/Ethnicity, Customized(participants) | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 1 | 3 | 7 |
| Black or African American | 0 | 0 | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 19 | 20 | 20 | 14 | 73 |
| Other | 1 | 0 | 1 | 0 | 2 |
| Mixed Race | 0 | 0 | 0 | 0 | 0 |
| Screening LDL-C Level(participants) | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin | Total |
|---|---|---|---|---|---|
| < 130 mg/dL | 9 | 9 | 9 | 8 | 35 |
| ≥ 130 mg/dL | 12 | 13 | 13 | 12 | 50 |
| LDL-C Concentration(mg/dL) | Placebo | Atorvastatin | Evolocumab | Evolocumab and Atorvastatin | Total |
|---|---|---|---|---|---|
| Mean | 118.1 ± 18.1 | 123.2 ± 21.3 | 118.2 ± 18.4 | 116.5 ± 23.7 | 119.1 ± 20.2 |
Ran from Jul 2014 to primary completion in Feb 2015, 7 months.
Results were first posted in Aug 2016, 1 year 6 months after primary completion. A results delay was requested in Jan 2016.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Evolocumab · Atorvastatin